Enanta Pharmaceuticals Inc (ENTA)

[Lishur]

Paxlovid sales for the first quarter came in at $4.1 billion, which far exceeded Wall Street's expectation of $2.7 billion. The result also was a $2.8 billion increase from the same period in 2022. Pfizer chalked up the performance to strong demand in China and to new launches in other international markets.


Pfizer’s infringement has damaged and will continue to damage Enanta, which is
entitled to recover damages adequate to compensate for Pfizer’s infringement in an amount to be
determined at trial, and in any event no less than a reasonable royalty for the use made by Pfizer
of Enanta’s invention.

PRAYERS FOR RELIEF
WHEREFORE, Enanta Pharmaceuticals, Inc. respectfully requests that this Court:
a. Enter judgment that Pfizer has infringed the ’953 Patent;
b. Award damages adequate to compensate Enanta for Pfizer’s infringement
together with pre-judgment and post-judgment interest and costs under 35 U.S.C.
§ 284;
c. Award treble damages for Pfizer’s willful infringement;
d. Enter judgment that this case is exceptional and award Enanta its reasonable
attorneys’ fees, costs, and expenses, under 35 U.S.C. § 285; and
e. Award such other and further relief as this Court may deem just and proper.